(Pyr1)-apelin-13 administration reduced glomerulosclerosis and interstitial fibrosis, while no differences were found in injury scores for other markers between TGA-PE treated with apelin compared with TGA-PE control (Table 3). The gene discussed is APLN; the disease is glomerulosclerosis.